Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OptimizeRx (OPRX) EBT (2016 - 2026)

OptimizeRx's EBT history spans 16 years, with the latest figure at $7.5 million for Q4 2025.

  • On a quarterly basis, EBT rose 238.36% to $7.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.9 million, a 135.85% increase, with the full-year FY2025 number at $7.0 million, up 135.85% from a year prior.
  • EBT hit $7.5 million in Q4 2025 for OptimizeRx, up from $1.0 million in the prior quarter.
  • Over the last five years, EBT for OPRX hit a ceiling of $7.5 million in Q4 2025 and a floor of -$11.7 million in Q4 2023.
  • Historically, EBT has averaged -$2.4 million across 5 years, with a median of -$3.1 million in 2023.
  • Biggest five-year swings in EBT: plummeted 8790.01% in 2022 and later surged 238.36% in 2025.
  • Tracing OPRX's EBT over 5 years: stood at $623462.0 in 2021, then crashed by 152.26% to -$325836.0 in 2022, then tumbled by 3503.04% to -$11.7 million in 2023, then surged by 118.81% to $2.2 million in 2024, then surged by 238.36% to $7.5 million in 2025.
  • Business Quant data shows EBT for OPRX at $7.5 million in Q4 2025, $1.0 million in Q3 2025, and $1.7 million in Q2 2025.